profit from every $100 of sales.
$0$100
Equillium
$1.32-7.04% today
+42.9% in 1 year
1-year low $0.841-year high $3.20
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2024.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Equillium sold, what it kept, and what it did with the cash.
Sales went from $15.8 million in 2022 to $0 in 2025, with -$22.4 million of profit last year.
SalesProfit
Equillium vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Equillium | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Equillium's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 16 | 36 | 41 | 0 | |
| – | – | – | – | |
| -39 | -15 | -8 | -24 | |
| -61 | -12 | -8 | -24 | |
| -62 | -13 | -8 | -22 | |
| -1.85 | -0.38 | -0.23 | -0.39 | |
| – | – | – | – | |
| -247.6% | -40.2% | -20.1% | – | |
| -396.1% | -37.0% | -19.6% | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 78 | 51 | 26 | 32 |
| Cash | 59 | 23 | 18 | 30 |
| Total debt | 10 | 1 | 0 | 1 |
| Total liabilities | 46 | 28 | 7 | 3 |
| 32 | 23 | 19 | 29 | |
| 34 | 35 | 35 | 57 | |
| -115.1% | -41.4% | -33.6% | -63.7% | |
| -195.4% | -59.1% | -42.3% | -78.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -9 | -22 | -19 | -23 | |
| 0 | 0 | 0 | 0 | |
| -9 | -22 | -19 | -23 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | 0 | – | |
| 5 | 4 | 4 | 2 |
Valuation
- –
- –
- –
- 3.7×
- 2.5×
- –
- –
- -18.5%
- -7.8%
- 0.0%
Profitability
- 0.0%
- -20.1%
- -19.6%
- 0.0%
- -33.9%
- -74.6%
- -61.4%
- -30.2%
- -34.1%
- –
Growth
- +61.5%
- –
- −19.3%
- –
- +33.6%
Financial health
- -2.2×
- 0.01
- 1.1%
- –
- 18.62
- 18.62
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 12%of 957
Bottom 11%of 889
Top 9%of 884
Bottom 4%of 986
What analysts expect
- Average price target
- $6.50
- Range
- $6.00 – $7.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.06 | -0.04 | −50.0% |
| Mar 25, 2026 | -0.04 | -0.07 | +42.9% |
| Nov 13, 2025 | -0.06 | -0.14 | +57.1% |
| Aug 14, 2025 | -0.16 | -0.14 | −14.3% |
| May 14, 2025 | -0.24 | -0.23 | −4.3% |
| Mar 27, 2025 | -0.16 | -0.22 | +27.3% |
| Nov 13, 2024 | -0.00 | -0.26 | +99.9% |
| Aug 8, 2024 | 0.01 | -0.15 | +106.7% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
26No pass
Benjamin Graham
40No pass
Philip Fisher
39No pass
Peter Lynch
71Pass
Joel Greenblatt
0No pass
Charlie Munger
31No pass
Terry Smith
38No pass
Questions about Equillium
Is Equillium a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Equillium AI analysis
What does Equillium do?
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. It is in Biotechnology.
Does Equillium pay a dividend?
No. Equillium does not pay a dividend at the moment.
Is Equillium stock halal?
Yes. Equillium passes our halal screen: its business is permitted and its debt is 0.7% of its market value, under the 30% limit. How we check
How has Equillium stock done over the past year?
Up 42.9% over the past twelve months, to $1.32. It traded between $0.84 and $3.20 and is 58.8% below its high.
Who are Equillium's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Equillium's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.